Supplementary Data — Losartan for COVID-19: real-time meta analysis of 6 studies

@CovidAnalysis, December 2025, Version 3V3
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Puskarich (DB RCT) -2% 1.02 [0.07-15.9] ICU 1/58 1/59 Improvement, RR [CI] Treatment Control Puskarich (DB RCT) -205% 3.05 [0.33-28.5] hosp. 3/58 1/59 Puskarich (DB RCT) -27% 1.27 [0.36-4.50] progression 5/58 4/59 COVID-ARB Geriak (RCT) 6% 0.94 [0.06-13.7] death 1/16 1/15 COVID-ARB Geriak (RCT) 53% 0.47 [0.05-4.65] ICU 1/16 2/15 COVID-ARB Geriak (RCT) 53% 0.47 [0.05-4.65] no disch. 1/16 2/15 ALPS-IP Puskarich (DB RCT) -3% 1.03 [0.47-2.27] death 11/101 11/104 ALPS-IP Puskarich (DB RCT) -26% 1.26 [0.54-2.91] death 11/101 9/104 ALPS-IP Puskarich (DB RCT) -27% 1.27 [0.71-2.27] ventilation 21/100 17/103 ALPS-IP Puskarich (DB RCT) 3% 0.97 [0.89-1.07] oxygen 89/101 94/104 COVIDMED Freilich (RCT) -533% 6.33 [0.43-92.5] death 4/9 0/3 COVIDMED Freilich (RCT) -160% 2.60 [0.43-15.7] hosp. time 9 (n) 3 (n) Götberg (RCT) 1% 0.99 [0.06-15.6] death 1/151 1/149 Götberg (RCT) 77% 0.23 [0.07-0.78] ventilation 3/151 13/149 Götberg (RCT) 36% 0.64 [0.31-1.32] ICU 11/151 17/149 ARBs CORONA II Tran (RCT) -14% 1.14 [0.57-2.15] death 16/171 16/170 ARBs CORONA II Tran (RCT) -10% 1.10 [0.49-2.41] death 11/171 10/170 ARBs CORONA II Tran (RCT) -1% 1.01 [0.70-1.38] ventilation 49/170 48/168 ARBs CORONA II Tran (RCT) -3% 1.03 [0.94-1.10] oxygen 149/170 144/170 ARBs CORONA II Tran (RCT) -75% 1.75 [0.69-3.93] ICU 11/78 6/77 Losartan COVID-19 outcomes c19early.org December 2025 Favors losartan Favors control
Fig. S1. All outcomes.